Likelihood Of Approval Matters When Evaluating A Drug Development Partner
Executive Summary
Despite having the lowest average likelihood of approval rating for US FDA regulatory decisions out of 18 disease groups, early-stage oncology deals continue to attract big price tags.
You may also be interested in...
With Medivation, Pfizer Sees A Chance For More Combinations
Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.
BMS Scoops Cormorant In $520M Immuno-Oncology Deal
Bristol-Myers Squibb Co. has bolstered its immuno-oncology ambitions by acquiring IL-8 focused Cormorant Pharmaceuticals AB, the 4-year old Swedish biotech. Cormorant’s shareholders are getting $95M up front with the promise of a further $425M if milestones are achieved.
Immuno-Oncology Attracts Big Deal Dollars For Biotechs
Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.